Zobrazeno 1 - 10 of 26 pro vyhledávání: '"Alex Adjei"'
1
Akademický článek
Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report
Autor: Aakash Desai, Sagar Rakshit, Radhika Bansal, Yash Ashara, Ashley Potter, Rami Manochakian, Yanyan Lou, Yujie Zhao, Vinicius Ernani, Panos Savvides, Anna Schwecke, Nicole Moffett, Craig Hocum, Konstantinos Leventakos, Alex Adjei, Randolph Marks, Julian Molina, Aaron S. Mansfield, Zong-Ming Chen, Anastasios Dimou
Publikováno v: Cancer Treatment and Research Communications, Vol 36, Iss , Pp 100743- (2023)
Introduction: We evaluated the risk factors and outcomes for patients who experienced hepatotoxicity after use of sotorasib in KRAS G12C mutated NSCLC. Methods: Retrospective review of medical records of patients with KRAS G12C mutated NSCLC who rece
Externí odkaz: https://doaj.org/article/64060590b792442dbb64a81f4fd7d58f
Zobrazit plný text záznamu
3
Akademický článek
Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
Autor: Aixa E. Soyano, Bhagirathbhai Dholaria, Julian A. Marin-Acevedo, Nancy Diehl, David Hodge, Yan Luo, Rami Manochakian, Saranya Chumsri, Alex Adjei, Keith L. Knutson, Yanyan Lou
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-9 (2018)
Abstract Background Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved overall survival (OS) and progression-free survival (PFS) in a subset of patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). To
Externí odkaz: https://doaj.org/article/11ea289281944b548836e77864549370
Zobrazit plný text záznamu
4
Akademický článek
Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana.
Autor: Abraham R Oduro, Seth Owusu-Agyei, Margaret Gyapong, Isaac Osei, Alex Adjei, Abena Yawson, Edward Sobe, Rita Baiden, Martin Adjuik, Fred Binka
Publikováno v: PLoS ONE, Vol 12, Iss 3, p e0174503 (2017)
BACKGROUND:Uncommon and rare adverse events (AEs), with delayed onset may not be detected before new drugs are licensed and deployed. The present study examined the post licensure safety of dihydroartemisinin-piperaquine (DHP) as an additional treatm
Externí odkaz: https://doaj.org/article/b68b9bf85e5d46a2b63d912376c9d261
Zobrazit plný text záznamu
5
Akademický článek
Multi-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with Electrocardiograms.
Autor: Abdunoor M Kabanywanyi, Rita Baiden, Ali M Ali, Muhidin K Mahende, Bernhards R Ogutu, Abraham Oduro, Halidou Tinto, Margaret Gyapong, Ali Sie, Esperanca Sevene, Eusebio Macete, Seth Owusu-Agyei, Alex Adjei, Guillaume Compaoré, Innocent Valea, Isaac Osei, Abena Yawson, Martin Adjuik, Raymond Akparibo, Mwaka A Kakolwa, Salim Abdulla, Fred Binka
Publikováno v: PLoS ONE, Vol 11, Iss 10, p e0164851 (2016)
The antimalarial drug piperaquine is associated with delayed ventricular depolarization, causing prolonged QT interval (time taken for ventricular de-polarisation and re-polarisation). There is a lack of safety data regarding dihydroartemisinin/piper
Externí odkaz: https://doaj.org/article/3d451ccfdd6c48b3a58ac3d40f494746
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje